BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 07, 2013
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Wk 10/4
Company Bank Analyst Coverage Opinion chg cls
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Baird Brian Skorney Downgrade Neutral (from outperform) -62% $2.72
Deutsche Bank Alethia Young Downgrade Hold (from buy)
Piper Jaffray Edward Tenthoff Downgrade Neutral (from overweight)
William Blair Y. Katherine Xu Downgrade Market perform (from outperform)
Skorney lowered his target to $4 from $12 after FDA did not lift a clinical hold on sovaprevir, a second-generation selective inhibitor of HCV NS3 protease (see BioCentury, Sept. 30). Skorney also said ACH-3012 plus sovaprevir and ribavirin led to "poor" rapid virologic response (RVR) data in HCV genotype 1a patients, which he believes calls into question whether ACH-3012 "is meaningfully differentiated from the rest of the NS5A space." Last month, Achillion reported interim Phase II data showing the combination led to RVR rates of 50-80% in HCV genotype 1a (see B18).
Young also...

Read the full 1168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >